RxDoctor Payments Data

Alvin Schmaier, MD

Hematology & Oncology · Cleveland, OHNPI 1578583134

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Merck at 30.9% of the total. Reporting peaked in 2019 at $11,745 and has fallen 94.9% since, to $603 in 2025.

$25,395in general payments, 2019–2025

Across 178 payments — averaging $142.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$8K
  • CSL Behring$8K
  • HEMA Biologics, LLC$3K
  • Shire North American Group Inc$2K
  • Dova Pharmaceuticals$1K
  • Sanofi$910
  • plus $3K from 37 others
$190,985in research payments, 2019–2025

Across 51 payments — averaging $3744.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$137K
  • Portola Pharmaceuticals, LLC$28K
  • Shire North American Group Inc$23K
  • Bioverativ Therapeutics Inc.$3K

What the payments were for

  • Consulting fees$10,16540%
  • Speaking & faculty fees$6,84027%
  • Travel & lodging$4,14316%
  • Food & beverage$4,24717%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,395 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio →

Medicare billing

Part B allowed, 2024
$15,139
Medicare patients
76
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PromactaEltrombopag Olamine17$254,724
EliquisApixaban132$142,992
XareltoRivaroxaban60$64,971
Fondaparinux Sodium20$13,082
Enoxaparin Sodium16$5,338
Mycophenolate Mofetil25$1,953
Celecoxib13$566
Folic Acid11$10

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisPromacta$233$254,72417 claims
PfizerEliquis$63$142,992132 claims
Johnson & JohnsonXarelto$16$64,97160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cleveland

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →